Category Archives: People

Stop Paying Lip Service to Patient-Centricity

by Michael Edwards Pharma has operated the same way for 100 years, but the US healthcare model has changed completely in the last 30 years, for payers, pharmacists, hospitals, and even at the clinician level. These changes necessitate pharma – a traditionally stagnant partner – to change now or further risk having its stubbornness result […]
Also posted in Corporate Responsibility, Guest Blog, leadership, Patient Communication, patient compliance, patient education, Strategy | Tagged , , , | Leave a comment

FDA Wants YOU!

A number of top management positions at the Center for Drug Evaluation and Research (CDER) need to be filled, and Center leaders are looking for experienced industry managers to help rebuild its staff. Many experienced FDAers are ending their careers or taking on new challenges, creating a need for “renewal and replenishment” of the agency, […]
Also posted in FDA, leadership, R&D, Regulatory | Tagged , , , | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, […]
Also posted in Advertising, Agency Insight, E-Media, Guest Blog, Marketing, Sales, social media, Strategy, Technology | Tagged , , , | Leave a comment

Pushing the Boundaries of MS Research: The Myelin Repair Foundation

R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
Also posted in Strategy | Tagged , , , | 1 Comment

New Fees Made FDA Worse for Generic Drug Approvals, Says GPhA Chairman

‘Actions’ don’t speak louder than words in dealing with FDA’s backlog of generic drug applications, says newly-elected GPhA Board Chairman Craig Wheeler. When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process […]
Also posted in FDA, Legal, Market Access, R&D, Regulatory, Strategy | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta